Mirataz™(mirtazapine transdermal ointment)
Mirataz is a transdermal formulation of mirtazapine under development to be used in cats for the management of weight loss. Mirataz is a novel product that utilizes KindredBio’s Accusorb™ technology and has been shown to result in measurable blood levels of mirtazapine.
1 U.S. Veterinarian Mirtazapine Phase 2 Research, Wise Insights, May 2016 (n=89 U.S. small animal veterinarians). U.S. Veterinarian Mirtazapine Phase Research, Ipsos, September 2016 (n=201 U.S. small animal veterinarians). Data on file at KindredBio.
2 Freeman LM, Lachaud MP, Rhodes L, and Zollers B. Evaluation of weight loss over time in cats with chronic kidney disease. J Vet Int Med. 2016; 30:1661-1666.
3 Agnew W and Kirman R. Pharmacological appetite stimulation: rationale choices in the inappetent cat. J Feline Med Surg. 2014 Sep; 16(9):749-56.
4 Quimby JM and Lunn KE. Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial. Vet J. 2013 Sep; 197(3):651-5.
5 Epub: Benson KK, Zajic LB, Morgan P, Brown S, Hansen RJ, Lunghofer PJ, Wittenburg LA Gustafson DL and Quimby JM. Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study. J Fel Med Surg. 2016 Sep 9. pii: 1098612X16667168.